JP Morgan Chase
CNTX icon

JP Morgan Chase’s Context Therapeutics CNTX Stock Holding History

JP Morgan Chase’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.5K Buy
+10,422
New +$24.3K ﹤0.01% 6460
2025
Q2 		– Sell
-80
Closed -$49 – 7154
2025
Q1 		$49 Sell
80
-86
-52% -$75 ﹤0.01% 6987
2024
Q4 		$174 Sell
166
-7
-4% -$12 ﹤0.01% 6928
2024
Q3 		$339 Buy
+173
New +$384 ﹤0.01% 6841
2024
Q2 		– Sell
-33
Closed -$46 – 7399
2024
Q1 		$46 Buy
33
+10
+43% +$11 ﹤0.01% 7055
2023
Q4 		$26 Buy
23
+7
+44% +$8 ﹤0.01% 7300
2023
Q3 		$24 Buy
+16
New +$18 ﹤0.01% 7131

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JP Morgan Chase's CNTX Position: Q1 2026 in Review

JP Morgan Chase opened a new position in Context Therapeutics (CNTX) in Q1 2026: 10,422 shares worth $25.5K. The stake represents ﹤0.01% of the portfolio and ranks #6460 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in CNTX as recently as Q1 2025.

JP Morgan Chase first reported a position in CNTX in Q3 2023 and has held it in 7 quarters since. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • JP Morgan Chase held 10,422 shares of Context Therapeutics worth $25.5K as of Q1 2026.
  • Context Therapeutics was a new JP Morgan Chase position in Q1 2026.
  • Context Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6460 holding.
  • JP Morgan Chase first reported a position in Context Therapeutics in Q3 2023 and has held it in 7 quarters since.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.